Turkish-German physicians Ugur Sahin and Ozlem Tureci behind promising corona jabWorld | 10 Nov 2020 5:09 pm
News that a Pfizer vaccine is 90 percent effective against the coronavirus diesease has been heralded as a turning point for now.
But while the vaccine has been bankrolled by the American pharmaceutical giant, the science itself is the work of BioNTech, a German company founded by married couple and dedicated physicians Ugur Sahin and Ozlem Tureci, Sky News reports.
Together, they are being hailed as the brains that allowed the potentially transformative coronavirus vaccine to come about.
Scientists and entrepreneurs Professor Sahin, 55, and Dr Tureci, 53, are now among the 100 richest Germans, with the value of their company BioNTech soaring to US$21 billion (£16 billion) in the wake of the vaccine breakthrough.
But, as children of immigrants, they came from humbler beginnings.
Chief executive BioNTech, Sahin was born in the Turkish city of Iskenderun, moving to West Germany at four years old. His father was a gastarbeiter, a migrant worker at a Ford factory in Cologne.
Dr Tureci, who is the chief medical officer, was born in Germany and is the daughter of a Turkish physician who migrated to the country from Istanbul.
Sahin trained as a doctor, studying in Cologne and Hamburg but turned his focus to researching immunotherapy. He met Dr Tureci early in his academic career.
Dr Tureci once said in an interview that even on the day of their wedding, they both made time for lab work.
The pair had a passion for research and oncology which they took forward into their first company Ganymed Pharmaceuticals which they set up in 2001.
The company set out to research the possibility of using modified genetic code, or Messenger RNA (mRNA), to trick the body into fighting cancer and develop cancer-fighting antibodies.
They sold this business in 2016 for US$1.4b (£1 billion). By then, they were already busy building BioNTech, founded in 2008, to pursue a much broader range of cancer immunotherapy tools.
The couple's work on the potential of mRNA proved to be vital in the development of the vaccine.
In January, Professor Sahin came across a scientific paper on a new coronavirus outbreak in the Chinese city of Wuhan.
It struck him how small the step was from anti-cancer mRNA drugs to mRNA-based viral vaccines.
BioNTech quickly assigned about 500 staff to project "light speed" to work on several possible compounds, winning pharma giant Pfizer and Chinese drug maker Fosun as partners in March.
Now trials have shown the vaccine, which uses mRNA genetic material to prompt the body to produce antibodies, is 90 percent effective
Colleagues describe Professor Sahin as "modest" and understated.
Matthias Theobald, a fellow oncology professor at Mainz University, where Professor Sahin still teaches, said: "He is a very modest and humble person. Appearances mean little to him.
"But he wants to create the structures that allow him to realise his visions and that's where is aspirations are far from modest."
Matthias Kromayer, a board member of venture capital firm MIG AG, whose funds have backed BioNTech, said: "Despite his achievements, he never changed from being incredibly humble and personable."-Photos: Sky News